SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.238
+0.001 (0.42%)
At close: Nov 20, 2024, 4:00 PM
0.235
-0.003 (-1.39%)
After-hours: Nov 20, 2024, 5:30 PM EST
SciSparc Employees
SciSparc had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$582,333
Profits / Employee
-$1,894,667
Market Cap
853.85K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TC Biopharm (Holdings) | 41 |
| LogicMark | 27 |
| Elevai Labs | 18 |
| Catheter Precision | 14 |
| Bluejay Diagnostics | 10 |
| Revelation Biosciences | 9 |
| ZyVersa Therapeutics | 7 |
SPRC News
- 7 weeks ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 2 months ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 2 months ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - GlobeNewsWire